關鍵數據
5.330今開
5.420最高
188.74K成交量
2.18本益比TTM
77.66本益比動
--股利TTM
0.24%換手率
5.370昨收
5.240最低
1.00M成交額
虧損本益比靜
0.95市淨率
0.00%股息率 TTM
37.51%ROA
13.02052週最高
0.10量比
-17.93M淨利潤
77.94M總股本
2.4327每股盈餘TTM
1.46Beta
65.59%ROE
5.10052週最低
8.10%振幅
75.66%毛利率
413.08M總市值
-1.03回報/風險
4.03%風險率

即將為您帶來更多新聞,敬請期待。 。 。
CorMedix Inc評分
0.04與上次評分對比預測8.67
財務診斷9.33
技術分析5.59
公司估值9.11
機構認同度5.00
風險評估4.14
分析師評級
買入評級
15.667目標均價
+175.10%漲幅空間
CorMedix Inc 最新財報電話會記錄
CorMedix (CRMD) 2026年第二季法說會:營收達1.019億美元,上調EBITDA指引
CorMedix 2026 年第二季營收達 1.019 億美元,調整後 EBITDA 為 5,870 萬美元,管理層並將全年 EBITDA 財測指引上調至 1.25 億至 1.4 億美元。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
CorMedix Inc 簡介
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
行業藥品
公司代碼CRMD
員工數量64
國家United States of America
持股情況
| 持股股東 | 佔比 |
|---|
| Deep Track Capital LP | 6.72% |
|---|
| BlackRock Institutional Trust Company, N.A. | 6.45% |
|---|
| Abdalkader (Shaibatalhamd Aymen) | 5.86% |
|---|
| Vanguard Capital Management, LLC | 3.99% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor | 27.10% |
|---|
| Investment Advisor/Hedge Fund | 13.41% |
|---|
| Hedge Fund | 10.76% |
|---|
| Individual Investor | 7.51% |
|---|
常見問題
CorMedix Inc(CRMD)的當前股價是多少?
CorMedix Inc(CRMD)的當前股價是 5.30。
CorMedix Inc股票的52週最高點是多少?
CorMedix Inc股票的52週最高點是13.02。
CorMedix Inc股票的52週最低點是多少?
CorMedix Inc股票的52週最低點是5.10。
現在CorMedix Inc(CRMD)的股票是買入、持有還是賣出?
根據分析師評級,CorMedix Inc(CRMD)的總體評級為買入,目標價格為15.67。
CorMedix Inc(CRMD)股票的每股收益(EPS TTM)是多少
CorMedix Inc(CRMD)股票的每股收益(EPS TTM)是2.43。